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ABSTRACT: The WNT pathway interconnects a network of signaling
events involved in a huge plethora of cellular processes, from
organogenesis to tissue homeostasis. Despite its importance, the
exiguity of organic drugs directly targeting the members of the Frizzled
family of WNT receptors has hampered progress across the whole
spectrum of biological ﬁelds in which the signaling is involved. We here
present FzM1.8, a small molecule acting as an allosteric agonist of
Frizzled receptor FZD4. FzM1.8 derives from FzM1, a negative
allosteric modulator of the receptor. Replacement of FzM1 thiophene
with a carboxylic moiety induces a molecular switch in the lead and
transforms the molecule into an activator of WNT signaling. We here
show that, in the absence of any WNT ligand, FzM1.8 binds to FZD4,
promotes recruitment of heterotrimeric G proteins, and biases WNT signaling toward a noncanonical route that involves PI3K.
Finally, in colon cancer cells, we prove that the FZD4/PI3K axis elicited by FzM1.8 preserves stemness and promotes
proliferation of undiﬀerentiated cells.
The 10 members of the human Frizzled (FZD) receptorfamily respond to the extracellular ligands of the wingless/
int1 (WNT) family of lipo-glycoproteins. They control
diﬀerentiation, organogenesis, and patterning in the developing
embryo and somatic stem cell maintenance, tissue homeostasis,
and regeneration in adult organisms. Dysregulation of WNT
signaling leads to cancer stem cell genesis and tumor
proliferation and has been linked to many types of
malignancies.1−4
Despite their involvement in many cellular processes, several
aspects of the mechanisms underpinning the activity of FZDs
are still obscure.5 The complexity arises from the multitude of
WNT/FZD combinations (19 WNT ligands for 10 FZDs) and
is further augmented by the many interconnected signaling
networks each pair can activate.6 Depending on the cascade,
WNT/FZD signaling may involve heterotrimeric G pro-
teins,7,8the cytosolic proteins Dishevelled (DVL),9 or small
GTPases.10 The existence of FZDs as oligomers11and the
participation of coreceptors like low-density lipoprotein
receptor-related proteins 5 and 6 (LRP5/6) or receptor TK-
like orphan receptor (ROR1/2)12 inﬂuence downstream
signaling and create additional levels of complexity.
In the “canonical” β-catenin-dependent pathway, binding of
WNT to FZDs recruits DVL at the plasma membrane (PM).
The WNT−FZD−DVL complex inactivates the APC destruc-
tion complex (formed by GSK3β, Axin, and Adenomatous
Polyposis Coli)13 and leads to the intracellular accumulation
and nuclear translocation of β-catenin. In the nucleus, β-catenin
regulates TCF/LEF-dependent transcription of WNT/β-
catenin target genes like cyclin D1, c-myc, and lgr5.
Progress in the WNT ﬁeld has been always hampered by the
enormous diﬃculties associated with obtaining recombinant,
pure, and biologically active WNTs and with the exiguity of
pharmacological compounds that can directly target FZDs. In
this complex scenario, small organic molecules acting as
orthosteric or allosteric agonists for FZDs would represent
essential biotools either for basic science or for pharmaceutical
application. Allosteric ligands oﬀer more options than
orthosteric ones. They may (i) present intrinsic agonist activity
(allosteric agonists), (ii) potentiate endogenous orthosteric
agonists [positive allosteric modulators (PAMs)], (iii) possess
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both properties mentioned above (ago-PAM), or (iv) inhibit
activation of the receptor [negative allosteric modulators
(NAMs)]. In addition, allosteric modulators may introduce a
“bias” that alters either the aﬃnity of their cognate receptor for
a speciﬁc agonist (ligand bias) or its propensity to activate a
speciﬁc downstream signaling pathway (signal bias).14
We have recently identiﬁed FzM1, a NAM of FZD4 (a FZD
family member).15 FzM1 binds to an allosteric binding site
located in intracellular loop 3 (ICL3) of FZD4 and alters the
conformation of the receptor, ultimately inhibiting the WNT/
β-catenin cascade.
Allosteric modulators exhibit fundamental changes in their
modes of eﬃcacy (known as a “molecular switch”) when minor
structural changes are made to their scaﬀold.16,17 The same
allosteric modulator can be thus converted into ago-PAMs,
PAMs, and NAMs.14,18 Here we show that the replacement of
the FzM1 thiophene with a carboxylic moiety induces a
molecular switch and generates, to the best of our knowledge,
the ﬁrst described allosteric agonist of FZD4, here termed
FzM1.8.
FzM1.8 potentiates the β-catenin pathway in the absence of
any WNT ligand. Upon binding, FzM1.8 biases FZD4 signaling
toward a FZD4/PI3K axis that culminates into transactivation
of β-catenin/TCF activity by the histone acetyltransferase
CBP/p300. The binding site, mechanism of action, and
competition with endogenous agonists are described here
together with the physiological role of the FZD4/PI3K
signaling axis.
■ MATERIALS AND EXPERIMENTAL PROCEDURES
Cell Cultures. HEK293, CaCo-2, HuH7.5, and U87MG
cells were grown in DMEM (41965-039, GIBCO, Thermo
Fisher Scientiﬁc) supplemented with 10% FBS (10270,
GIBCO), Glutamax (35050-061, GIBCO), and Pen/Strep
(15070-063, GIBCO). HEK293 transfection was performed
using PEI.15 CaCo-2 and HuH7.5 transfection was performed
using Lipofectamine (Invitrogen) following the manufacturer’s
instructions. Cell viability was measured with Trypan blue and
propidium iodide. The percentage of apoptotic cells was
measured with Mitotracker red (Life Technologies) following
the manufacturer’s instructions.
DNA. All DNA constructs were synthesized at GenScript.
The cDNAs encoding N-terminally HA-tagged FZD4wt (HA-
FZD4-wt) and mutants HA-FZD4-T425A and HA-FZD4-
T425D were all cloned in expression vector pCDNA3.1
(Invitrogen). For the reporter construct WRE-GFP-wt, eight
repeats of the optimized TCF/LEF binding sequence (5′-
AGATCAAAGGGG-3′) (interspersed with the 5′-GTA-3′
triplet) were positioned upstream from a minimal TATA box
promoter (5′-tagagggtatataatggaagctcgaattccag-3′) and a
KOZAC region (5′-cttggcattccggtactgttggtaaaaagcttggcattccgg-
tactgttggtaaagccacc-3′). The sequence was cloned in vector
pCDNA 3.1 (+) GFP between the restriction sites for NruI and
HindIII. This replacement substitutes for the CMV promoter of
the original vector with the TCF/LEF responsive sequences.
The correctness of the sequences was veriﬁed by DNA
sequencing. Control reporter construct WRE-GFP-mut was
obtained by mutagenesis of WRE-GFP-wt and presents the
eight repeats of the TCF/LEF binding sequence mutated to 5′-
AGGCCAAAGGGG-3′. A reporter construct (cmv-GFP)
presenting GFP under the control of the CMV promoter was
used as a control. The plasmid necessary for the expression of
human AKT mutant AKT-K179M was kindly provided by G.
Condorelli (Naples, Italy).
TCF/LEF Activity Measurement Using the WRE-GFP
Constructs. HEK293 cells were seeded (5 × 103 per well) in
96-well black Optyplates (PerkinElmer). After 24 h, cells were
co-transfected with both WRE-GFP-wt (or where indicated
WRE-GFP-mut) and HA-FZD4-wt. Transfection mixtures were
prepared as follows. In each well, 0.25 μg of PEI (pH 7.0) was
supplemented with 0.08 μg of DNA (both diluted in 4 μL of
DMEM). The mixture was incubated at room temperature for
30 min, diluted in culture medium, and added to the cells.
Twenty-four hours after transfection, the medium was replaced
and cells were incubated with FzM1 and FzM1.8 at the
indicated concentrations for the indicated times. When
reported, cells were supplemented with either CKI 7
dihydrochloride (5 μM), NFAT inhibitor (10 μM), bisindo-
lylmaleimide II (7.5 μM), Ly294002 (10 μM), Suramin
hexasodium salt (10 μM), Gallein (10 μM), or I-CBP 112
(7.5 μM). At the end of the incubations, cells were ﬁxed in
3.7% formaldehyde in PBS (pH 7.4) for 30 min. Formaldehyde
was quenched by incubating the cells for 30 min in 0.1 M
glycine in 1× PBS. The activity of the compounds was
evaluated by measuring GFP expression.
WNT5A-Conditioned Medium. Human glioblastoma
U87MG cells were the source of WNT5A-conditioned
medium.39 Conﬂuent 6 cm plates of U87MG cells were
incubated for 3 days in DMEM, 10% FBS, and Glutamax in the
absence of antibiotics. Conditioned medium was thus collected
and stored at −20 °C. Cells were then rinsed with fresh
medium and cultivated for an additional 3 days. The
conditioned medium obtained after the second incubation
was pooled with the ﬁrst portion. The pooled conditioned
medium was used to stimulate TCF/LEF activity in HEK293
cells.
Antibodies. The following antibodies were used. The
mouse monoclonal anti-HA peptide (HA-7) (H3663, Sigma-
Aldrich) was used at a 1/2000 dilution for both Western
blotting (WB) and immunoﬂuorescence (IF), while a 1/200
dilution was used for immunoprecipitation (IP). Mouse
monoclonal anti-α-tubulin (10D8, sc-53646, Santa Cruz
Biotechnology, Santa Cruz, CA) (WB, 1/200), rabbit
polyclonal anti-β-catenin (H-102, sc-7199, Santa Cruz Bio-
technology) (WB, 1/1000), rabbit polyclonal anti-HA peptide
(H6908, Sigma-Aldrich) (WB, 1/2000; IF, 1/500; IP, 1/500),
rabbit anti-AKT (9272, Cell Signaling Technology, Danvers,
MA) (WB, 1/1000), rabbit anti-phospho-AKT (Thr308)
(D25E6, 13038, Cell Signaling Technology) (WB, 1/2000),
rabbit anti-phospho-AKT (Ser473) (D9E, 4060, Cell Signaling
Technology) (WB, 1/2000), goat anti-rabbit IgG (H&L)
DyLight 594 conjugate (GtxRb-003-D594NHSX, ImmunoRe-
agents, Inc., Raleigh, NC) (IF, 1/500), donkey anti-rabbit IgG
(H&L) HRP conjugate (DkxRb-003-DHRPX, ImmunoRe-
agents, Inc.) (WB, 1/4000), goat anti-mouse IgG (H&L)
DyLight 594 conjugate (GtxMu-003-D594NHSX, ImmunoRe-
agents, Inc.) (IF, 1/500), goat anti-mouse IgG (H&L) HRP
conjugate (GtxMu-003-DHRPX ImmunoReagents, Inc.) (WB,
1/4000) were also used.
Western Blotting. Cells were lysed in 50 mM Hepes-KOH,
150 mM NaCl, and 1% Triton X-100, supplemented with
protease inhibitors (Roche). Lysates were centrifuged at 14000
rpm for 30 min at 4 °C. The total amount of proteins in each
lysate was measured using the Bradford assay. Before sodium
dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−
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PAGE), each lysate was diluted in 20 mM Tris-HCl (pH 6.8),
50 mM DTT, 1% SDS, 5% glycerol, and bromophenol blue and
then boiled for 10 min at 95 °C (for SDS analysis of FZD4,
lysates were not boiled but incubated for 30 min at 37 °C).
SDS−PAGE gels were run at 100 V (25 °C). For Western
blotting analysis, proteins were transferred onto PVDF
membranes (IB24001, Invitrogen, Thermo Fisher Scientiﬁc)
using the iBlot 2 Gel Transfer Device (Invitrogen, Thermo
Fisher Scientiﬁc). After the transfer, PVDF membranes were
ﬁrst incubated in a blocking solution (1× PBS, 5% nonfat dried
milk) for 2 h at 25 °C and then incubated with primary and
secondary antibodies supplemented with 0.3% nonfat dry milk.
ECL reactions were performed as previously described.15 The
immunoreactive bands were detected by chemiluminescence
and quantitated using ImageQuant (GE Healthcare, Little
Chalfont, U.K.).
Immunoﬂuorescence. Immunoﬂuorescence was assessed
as previously described.15 Brieﬂy, HEK293 cells seeded at a
density of 5000 cells/well in a ViewPlate-96 Black, Optically
Clear Bottom plate (6005182, PerkinElmer) were transfected
with PEI as described above. Huh7.5 cells growing on glass
coverslips were transfected with Lipofectamine 2000 (11660-
019, Invitrogen), according to the manufacturer’s instructions.
The cells were ﬁxed in 3.7% formaldehyde in PBS (pH 7.4) for
30 min. Formaldehyde was quenched by incubating the cells for
30 min in 0.1 M glycine in 1× PBS. Then cells were
Figure 1. FzM1.8 is an allosteric agonist of FZD4 and activates the WNT/β-catenin pathway. (A) Chemical structures of FzM1 and FzM1.8. (B and
C) Dose−response curves for FzM1 and FzM1.8 modulation, respectively, of the WNT/β-catenin pathway in HEK293 cells expressing FZD4-wt.
Values indicate changes in WRE activity (expressed as the percentage of change over basal activity). (D) Dose−response curves for FzM1.8
modulation of WRE activity in HEK293 cells expressing FZD4wt (red) or FZD4-T425A (black). (E) Response elicited by incubating HEK293 cells
(transiently expressing FZD4-wt) with FzM1.8 (2 μM, red) or WNT5A (conditioned medium, black) for the indicated period of time. Values are
reported as means ± the standard error of the mean (n = 5).
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permeabilized using 0.1% Triton in PBS (pH 7.4) for 10 min at
25 °C and then incubated with the appropriate dilution of
primary and secondary antibodies in PBS for 1 h and 45 min,
respectively.
Endocytosis Assay. HuH7.5 cells growing on glass
coverslips were transfected with HA-FZD4-wt. Twenty-four
hours after being transfected, cells were incubated for 1 h at 4
°C in Leibovitz L15 Medium (L0300, Microgem) containing
FBS 10%, in the presence or absence of the indicated
concentration of FzM1.8. After being incubated, cells were
warmed to 37 °C for 1 h, ﬁxed in 3.7% formaldehyde, and
processed for immunoﬂuorescence.
Alkaline Phosphatase Assay. Alkaline phosphatase
activity was measured by colorimetric detection of p-nitro-
phenol. After CaCo-2 cells had been cultured with the indicated
compounds, cell culture medium was gently removed from the
cultures and cells were washed twice with PBS. Cells were then
incubated with a solution of 2.5 mg/mL p-nitrophenyl
phosphate dissolved in 100 mM diethanolamine, 150 mM
NaCl, and 2 mM MgCl2 at pH 9.5 for 60 min. After the
incubation, the solution was transferred to a new tube, and 0.17
M NaOH was added to stop the reaction. The absorbance was
read at OD405 in a microplate reader.
Excision and Culturing of Human Biopsies from
Familial Adenomatosis Poliposis (FAP) Patients. Biopsies
from FAP patients were kindly provided by G. B. Rossi. The
study was approved by the Ethics Committee of the University
of Naples Federico II. Immediately after excision, biopsies were
rinsed in physiological saline. Samples were then digested with
trypsin for 10 min at room temperature and centrifuged at 400
rpm for 10 min at room temperature. Isolated cells present in
the supernatant were then counted and cultured at a conﬂuency
of 100000 cells/mL in DMEM supplemented with 10% FBS,
Glutamax, and Pen/Strep. Where indicated, FzM1 and FzM1.8
were added at concentrations of 15 and 5 μM, respectively.
After incubation for 24 and 48 h, cell viability was measured
with the Trypan blue assay and propidium iodide.
Statistical Analysis. EC50 values were calculated from
dose−response data using nonlinear regression analysis of
Prism version 6.0 (GraphPad, GraphPad Software, San Diego,
CA). All data were analyzed using the two-tailed Student’s t
test. A two-way analysis of variance test was used to compare
columns. P values of <0.05 were considered statistically
signiﬁcant.
In Silico FZD4 Model. Three-dimensional (3D) in silico
models of FZD4 in complex with Gαs and the hypothetical
binding modes for FzM1 and FzM1.8 were generated using the
CCP4 suite (CCP4 Software), as previously described.15 The
crystal structure of the smoothened receptor [Protein Data
Bank (PDB) entries 4N4W and 4JKV]19 and the crystal
structure of the β2 adrenergic receptor−Gαs protein complex
(PDB entry 3SN6)20were both used as templates for the TMD
of FZD4 and for the FZD4/Gαs models, respectively. β2
adrenergic receptor and FZD4 sequences were structurally
aligned using the FFAS-3D and I-TASSER servers. Five 3D
models of FZD4 were generated and scored using the available
scoring functions of SPICKER and through visual inspections.
The geometry of the ﬁnal FZD4, FZD4/Gαs, FZD4/FzM1.8/
Gαs, and FZD4/FzM1/Gαs complex models was optimized
using several cycles of force ﬁeld minimization. Cartoons were
generated as previously described.15
■ RESULTS AND DISCUSSION
A Molecular Switch Converts FzM1 in Allosteric
Agonist FzM1.8. To induce a molecular switch in FzM1, we
generated a small library of FzM1 analogues (Figure S1). We
attempted mode switching by replacing the naphthyl, the
phenol, the thiophene, or the ureidic linker of FzM1. The
activity of the new compounds was assayed in HEK293 cells
transiently expressing both FZD4 and a WNT reporter
construct, the latter presenting the coding sequence of GFP
under the control of an optimized WNT responsive element
(WRE-wt). Compared to that of mock transfected cells,
transient expression of FZD4 did not induce activation of the
WNT reporter construct, indicating a low level of basal activity
of FZD4 in the absence of ligands. On other hand, activation of
the WNT/β-catenin canonical pathway by the GSK3-β
inhibitor LiCl (Figure S2A−C) or upon treatment with
FZD4 agonist WNT-5A (below) induced GFP expression
and increased the ﬂuorescence of the cells. Replacement of
FzM1 thiophene with either a carboxylic or a carboxyl ester
group induced a molecular switch in the lead and transformed
FzM1 into two new allosteric agonists of FZD4. In the absence
of any orthosteric ligand, the two compounds 3-hydroxy-5-[3-
(naphthalen-2-yl)ureido]benzoic acid [FzM1.8 (Figure 1A−
C)] and 3-hydroxy-5-[3-(naphthalen-2-yl)ureido]benzoic acid
[FzM1.10 (Figures S1−S3)] were able to increase WRE activity
in FZD4-expressing HEK293 cells. All the other synthesized
analogues of FzM1 (Figure S1) did not increase WRE activity
and acted as WNT inhibitors (Figure S3). Like FzM1, FzM1.8
did not increase WRE activity in cells not expressing FZD4
(Figure S4C,D), indicating that the eﬀect of the compound is
dependent on FZD4. Moreover, FzM1.8 did not induce GFP
expression in cells transiently expressing both FZD4 and either
a mutated nonfunctional WRE reporter [WRE-mut (Figure
S4E,F)] or a DNA construct in which a CMV promoter
controls GFP expression [cmv-GFP (Figure S4G)]. These
results conﬁrm that FzM1.8 does not act as general
transcriptional activator and that, instead, its activity relies on
a functional WRE.
Interestingly, in the range of concentrations tested, the two
compounds modulated WRE activity with values ﬁtting
hormetic dose−response curves (described in eq I).
=
+ −
+
+ −
+
− ×
− ×
fluorescence background
fluorescence max background
1 10
fluorescence max background
1 10
(log EC log[X]) Hill slope
(log EC log[X]) Hill slope
50act act
50inh inh (I)
For each of the two allosteric ligands, we measured both a
stimulatory activity [for FzM1.8, EC50 of activation (log
EC50act) ± the standard error of the mean (sem) = −6.4 ±
0.2; n = 16] and an inhibitory activity [EC50 of inhibition (log
EC50inh) ± sem = −5.5 ± 0.1; n = 16] (Figure 1C). EC50act and
EC50inh of the two compounds fall in the same concentration
range (Figure 1C and Figure S3), with FzM1.8 presenting an
eﬃcacy of stimulation that is higher than that of FzM1.10.
Using site-directed mutagenesis and hydrogen-to-deuterium
exchange (HDX) analysis, we have previously identiﬁed FZD-
ICL3 as the site addressed by FzM1.15 The compound contacts
ICL3 residue Thr-425, and its binding reduces the solvent
accessibility of this region of the receptor.15 Despite presenting
a switch in its activity, FzM1.8 contacts the same binding sites
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of the original lead. As already shown for FzM1, HEK293 cells
transfected with FZD4 mutant FZD4-T425A only partially
responded to FzM1.8 treatment (Figure 1D). Moreover, HDX
analysis reveals that FzM1.8 binding reduced the solvent
accessibility of ICL3 (Figure S5 and Tables S1−S3).
Interestingly, both ligands aﬀected the conformation of TM6,
Figure 2. FZD4/FzM1.8 complex activates PI3K. (A−D) Dose−response curves for FzM1.8 modulation of WRE activity in cells expressing FZD4wt
in the presence of NFAT, PKC, PI3K, and CBP/p300 inhibitors, respectively. (E) Schematic cartoon depicting the involvement of FZD4 in the
WNT/PI3K pathway. Values are reported as means ± sem (n = 5). *P < 0.05.
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with FzM1.8 increasing the solvent accessibility of this section
of the receptor more than FzM1 did (Figure S5 and Tables
S1−S3).
Binding of FzM1.8 to FZD4 Initiates a Noncanonical
WNT Signaling Route. Treatments with FzM1.8 as short as
15 min were suﬃcient to achieve maximal activation of the
WNT responsive elements. This timing was similar to that
required by WNT5A (Figure 1E) and compatible with a
signaling pathway originating soon after binding of the ligand to
its cognate receptor.
Regardless, we performed a set of experiments to exclude
other unrelated signaling explanations for modulation of FZD4
by FzM1.8. Below 30 μM and in the time window of the
experiment (treatment for ≤48 h), FzM1.8 did not aﬀect the
HEK293 cell proliferation rate or induce cell death or apoptosis
or arrest the growth of the cultures (Figure S6A−C). This
proves that stimulation, as well as inhibition, of the WRE
activity measured upon treatment with low and high
concentrations of FzM1.8, did not depend on an increased
level of duplication of the cells or the toxicity of the compound,
two common causes of hormesis. FzM1.8 does not aﬀect
maturation or PM localization of FZD4. This was shown in
HEK293 cells as well as in human hepatoma HuH7 cells, that
for their ﬂat shape better suits immunoﬂuorescence studies of
PM-localized proteins (Figure S7). Finally, in a manner
diﬀerent from that of FZD antagonist Niclosamide,23 FzM1.8
did not induce FZD4 endocytosis (Figure S8).
Figure 3. FzM1.8 activity involves G protein signaling. (A) Dose−response curves for FzM1.8 modulation of WRE activity in the presence of
Suramin (black) or Gallein (red). (B) Schematic cartoon depicting the pathway elicited by FzM1.8 (yellow) upon binding to FZD4. (C) FZD4/
FzM1.8/Gα in silico model that inspired the mutants described herein: FZD4 transmembrane domain (brown cartoon, in which numbers indicate
TM helices of FZD4), Gα subunit (cyan cartoon), and FzM1.8 (yellow molecular surface) (FZD4 extracellular domain omitted for the sake of
clarity). (D−G) Proposed mode of binding of FzM1.8 (yellow balls and sticks). The FzM1.8 binding site is located at the interface between FZD4
ICL3 (brown cartoon) and helices H3−H5 of the Gα subunit (cyan cartoon). The negatively charged carboxyl group of FzM1.8 (H) but not the
thiophene of FzM1 (I) contacts Gα-R389 on helix 5 of the G protein. Values are reported as means ± sem (n = 5). *P < 0.05.
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Thus, upon binding to FZD4, allosteric agonist FzM1.8
initiates a signaling route resulting in increased WRE activity.
We started testing if FzM1.8, by either aﬀecting FZD4/DVL
interaction or inhibiting β-catenin proteasomal degradation,
was acting via the WNT canonical pathway (Figure S9A). As
shown in Figure S9B, in the presence of FzM1.8, FZD4 can still
recruit DVL. Furthermore, in a manner diﬀerent from that of
WNT ligands or LiCl, FzM1.8 did not increase intracellular
levels of β-catenin (Figure S9C). Finally, in the presence of
CIK 7, a pan-inhibitor of casein kinase I,21 a protein involved in
activation of the FZD4/DVL complex,22 FzM1.8 stimulatory
activity was mostly preserved (Figure S9D). Thus, the FzM1.8/
FZD4 complex stimulates WRE activity but does not aﬀect
proteins taking part in the FZD4/DVL/APC axis.
The FZD4/FzM1.8 Complex Activates a WNT Signal-
ing Route That Involves PI3K. To explain FzM1.8 activity,
we thus hypothesized the involvement of a noncanonical
pathway. The WNT/Ca2+, PCP, and WNT/ROR pathways are
inhibitory toward the canonical WNT/β-catenin pathway, and
thus, their involvement would not explain FzM1.8 stimulatory
activity. Moreover, inhibition of two known modulators of the
WNT/Ca2+ pathway, PKC by bisindolylmaleimide24 and
NFAT by the NFAT inhibitor peptide,25 had no eﬀect on
FzM1.8 activity (Figure 2A,B), further excluding the involve-
ment of the WNT/Ca2+ pathway.
The only pathway that has been described as a positive
modulator of the WNT canonical pathway is the one involving
phosphatidylinositol-4,5-bisphosphate 3-kinases (PI3Ks).2
PI3K has been already shown to aﬀect the WNT canonical
pathway on multiple levels. In diﬀerentiated myoﬁbers, binding
of orthosteric ligand WNT7a to FZD7 directly activates the
PI3K pathway and induces myoﬁber hypertrophy.26 Moreover,
via AKT, PI3K inhibits GSK3-β and leads to β-catenin
stabilization.27 Alternatively, AKT has been shown to promote
the activity of histone acetyltransferases CBP and P300, both
trans-activators of the β-catenin/TCF transcription complex.28
These remodel the chromatin bound to WNT responsive
genes, ultimately boosting the activity of the β-catenin/TCF
transcription complex. Indeed, in the presence of PI3K
inhibitor Ly294002,29 FzM1.8 lost its ability to induce WRE
activity (Figure 2C). WB analysis of cells treated with FzM1.8
revealed an increase in the level of AKT phosphorylation at
Thr-308 after incubation with the ligand for 30 min and 2 h,
conﬁrming the involvement of PI3K in the pathway activated
by FzM1.8. Diﬀerently, we did not measure an increase in the
level of AKT phosphorylation at Ser-473 (Figure S10). Finally,
HEK293 cells expressing both FZD4 and the AKT dominant
negative mutant AKT K179M were insensitive to FzM1.8,
further proving the involvement of the protein kinase in the
WRE activation elicited by the ligand (Figure S10).
Because FzM1.8 does not induce β-catenin stabilization
(Figure S9C), we tested whether activation of WRE by FzM1.8
was dependent on CBP/p300. In the presence of the CBP/
p300 speciﬁc inhibitor I-CBP 112,30 FzM1.8 activity was
drastically reduced (Figure 2D), conﬁrming the involvement of
PI3K and CBP/p300 downstream of the pathway activated by
FzM1.8.
The involvement of CBP/p300 indicates also that the FZD4/
PI3K axis elicited by FzM1.8 is “ancillary” to the canonical
WNT pathway. Even if it bypasses the WNT/FZD/APC
canonical route, the FZD4/PI3K axis acts ultimately on the
nuclear pool of β-catenin (Figure 2E).
Structural Details of FZD4/PI3K Axis Activation by
FzM1.8. PI3K activation by GPCRs involves heterotrimeric G
proteins.31 In the presence of Suramin, an inhibitor of G
proteins binding to GPCRs,32 treatment with FzM1.8 did not
increase WRE basal levels (Figure 3A), suggesting that FzM1.8
stimulates the assembly of a FZD4/heterotrimeric G protein
complex. Interestingly, the inhibitor of Gβγ activity, Gallein,33
also abolished FzM1.8 activity (Figure 3A). PI3K activation by
the FzM1.8/FZD4 complex thus requires binding of hetero-
trimeric G proteins, activation of the latter, and consequent
release of the βγ subunit (Figure 3B). In the basal state, FZD4
is inactive (Figure S2). When an allosteric ligand imposes a
speciﬁc conformation on the cognate receptor and forces it to
elicit a speciﬁc pathway, it is said to be endowed with signal bias
activity. Very likely, binding of FzM1.8 to ICL3 of FZD4
stabilizes a FZD4 conformation with increased aﬃnity for
heterotrimeric G proteins. Probably, FzM1.8 binding increases
the GTP exchange factor (GEF) activity of FZD4, causing the
release of the βγ subunit, which in turn activates PI3K.
To conﬁrm our model, we generated a set of FZD4 mutants
to mimic a FzM1.8-bound FZD4 conformation. To choose the
right amino acid substitutions, we built an in silico model for the
FZD4/FzM1.8/G protein complex. The closest receptor to use
as a possible FZD4 template would have deﬁnitely been the
human class F GPCR smoothened receptor (Smo), whose
crystal structures in complex with several of its orthosteric
ligands have been recently disclosed.19 However, none of these
structures are in complex with a G protein, and more
importantly, the electron density for ICL3 of Smo is missing
in almost all deposited structures of Smo. We thus decided to
generate a 3D model of FZD4 using as an additional template
the only available crystal structure of a GPCR/G protein
complex, the β2 adrenergic receptor/Gαs protein complex
(PDB entry 3SN6)20 (Figure 3E). FzM1.8 binds to ICL3 of
FZD4, contacting Thr-425 of the receptor (Figure 1D), and
thus, docking of FzM1.8 was focused on a pocket formed by
FZD4 ICL3 and the Gα subunit.34 The resulting hypothetical
binding mode is depicted in Figure 3D−G. The naphthyl
moiety of FzM1.8 lies in a small apolar pocket formed by Gα-
Y358G.h4s6.20 (CGN, common Gα numbering), Gα-W277G.H3.13,
and Gα-T350G.h4s6.3 and by FZD4 I416. The ureidic linker
contacts Gα-G353G.h4s6.9. The hydroxyl of the phenol ring
contacts FZD4 T425 and FZD4 D423. Finally, the carboxyl
moiety of FzM1.8 addresses FZD4 K249 and Gα R389G.H5.21.
In our models, the negatively charged carboxyl group of
FzM1.8 but not the thiophene of FzM1 contacts R389G.H5.21.
The G.h5.21 residue is highly conserved in all the Gα
paralogues and is essential for both GTP/GDP exchange and
dissociation of the β/γ subunit.35,36
A FZD4-wt/FZD4-T425D Heterocomplex Mimics
FZD4-wt Bound to FzM1.8. According to our in silico
model, the negative charge of FzM1.8 increases FZD4 GEF
activity by contacting a conserved positive residue on helix H5
of the Gα subunit. We thus attempted to mimic a FZD4/
FzM1.8 complex by generating a FZD4 mutant in which Thr-
425 was replaced with a negatively charged Asp residue.
When expressed in cells, FZD4-T425D folds properly as
shown by its correct intracellular localization on the PM of the
cells (Figure S11). Moreover, the mutant can still recruit DVL,
indicating that the amino acid substitution did not aﬀect
FZD4/DVL interaction (Figure S12). Like the FZD-T425A
mutant (Figure 1D), FZD4-T425D does not respond to
FzM1.8 treatment (Figure 4A), very likely because of the
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repulsion between the negative charge of FzM1.8 and the side
chain of D425.
Cells transfected with only FZD4-T425D did not present an
increased WRE basal activity (Figure 4B); on the contrary, they
presented a diminished one. Thus, FZD4-T425D does not
mimic a FZD4-wt/FzM1.8 complex. However, because FZD4-
wt is an obligate oligomer,37,38 we moved to co-express FZD4-
T425D and FZD4-wt to ultimately test how the WRE basal
activity and the response to FzM1.8 were inﬂuenced by FZD4-
wt/FZD4-T425D hetero-oligomers.
FZD4-T425D exerted a dominant negative eﬀect on FZD4-
wt signaling elicited by FzM1.8. Co-transfection of HEK293
cells with a mixture of cDNAs encoding FZD4-wt and FZD4-
T425D in a 3:1 ratio, despite strongly favoring expression of
the wt receptor, impaired the response of FZD4 to FzM1.8
treatment (Figure 4A). This suggests that the oligomeric state
of FZD4 inﬂuences the response to FzM1.8.
Diﬀerently, as shown in Figure 4B, WRE basal activity was
favored by the co-expression of FZD4-wt with FZD4-T425D.
In the absence of the agonist, a 2:1 ratio of FZD4-wt to FZD4-
T425D was enough to induce WRE basal activity. Moreover,
such activity was sensitive to Ly294002 (Figure 4C), indicating
the pathway activated by the hetero-oligomer is partially relying
on the FZD4/PI3K axis. Thus, mutant FZD4-T425D seems to
indeed mimic a FZD4/FzM1.8 complex because it biases FZD4
signaling toward the same PI3K pathway elicited by binding of
FzM1.8 to FZD4. However, it does so only when it forms,
together with FZD4-wt, a FZD4-wt/FZD4-T425D hetero-
complex.
FzM1.8 Acts as a NAM for FZD4 Signaling Elicited by
WNT5A. Many allosteric agonists are endowed with Ago-PAM
or Ago-NAM activity; i.e., they can modulate downstream
signaling events and simultaneously aﬀect binding of their
cognate receptors to orthosteric ligands. To prove FzM1.8 is an
Ago-PAM or an Ago-NAM for FZD4, we measured the eﬀect
of FzM1.8 treatment39 on the WRE activity induced by a FZD4
orthosteric ligand, the protein WNT5A. Activation by the
agonist was dependent on FZD4 and on the presence of a wild-
type TCF/LEF promoter. As shown in Figure S13, when
FZD4-expressing HEK293 cells were incubated with WNT5A-
conditioned medium,40 WRE activity increased.
FZD4-expressing cells were treated with WNT5A-condi-
tioned medium in the presence of either FzM1 or FzM1.8.
FzM1 works eﬃciently as a NAM for FZD4 and reduces
WNT5A-dependent WRE activity [log EC50inh ± sem = −6.2 ±
0.2 (Figure 5A)].15,41 Diﬀerently, in the presence of WNT5A,
FzM1.8 modulates WRE activity (Figure 5B) with dose−
response values ﬁtting a hormetic triphasic curve (described in
eq II).
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Two distinct inhibitory phases [log EC50inh1 ± sem = −5.5 ±
0.2, and log EC50inh2 ± sem = −7.8 ± 0.2 (n = 16)] are
interwoven with a stimulatory one [log EC50act ± sem = −6.7 ±
0.1 (n = 16)]. The bell-shaped section of the dose−response
curve (−6.5 < log[FzM1.8] < −5.5) is independent of WNT5A
and is the result of FzM1.8 allosteric agonist activity. When
FzM1.8 treatment was performed in the presence of both
WNT5A and Ly294002, this section of the dose−response
curve disappeared (Figure 5D). A comparison of the FzM1.8
dose−response curves measured in the presence (Figure 5C)
and absence (Figure 1C) of WNT5A reveals that EC50act and
EC50inh, as well as the WRE stimulatory eﬃcacy of FzM1.8, are
Figure 4. Mutant FZD4-T425D mimics FZD4 bound to FZM1.8. (A)
Dose−response curves for FzM1.8 modulation of WRE activity in cells
transfected with cDNA encoding FZD4wt (red dots), FZD4-T425D
(stars), or a mixture of them. FZD4wt:FZD4-T425D cDNA ratios of
3:1 (gray dots), 2:1 (●), 1:1 (+), 1:2 (|), and 1:3 (○). (B) Eﬀect of
co-expression of FZD4wt and FZD4-T425D at diﬀerent ratios on basal
WRE activity. (C) Eﬀect of Ly294002 on the basal WRE activity
elicited in HEK293 cells by the expression of FZD4wt, FZD4-T425D,
and FZD4-T425A homo-oligomers or FZD4wt/FZD4-T425D hetero-
oligomers. In panel A, values are reported as means ± the standard
deviation (n = 5); in panels B and C, values are reported as means ±
sem (n = 5). *P < 0.05.
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only minimally altered by the presence of the orthosteric
agonist. This indicates that WNT5A binding does not aﬀect, by
increasing or decreasing, FzM1.8-dependent signaling.
We thus moved to record dose−response curves of WNT5A
in the presence of a ﬁxed concentration of FzM1.8 (Figure 5E).
Incubation with the allosteric ligand decreased the potency of
WNT5A, indicating that FzM1.8 acts as a NAM for FZD4
signaling elicited by WNT5A.
Why, in the presence of Ly294002, is the WNT5A potency
not fully restored (Figure 5D)? While FzM1.8 stimulatory
activity is blocked by the PI3K inhibitor, WNT5A is inhibited
by the molecule (Figure 5D). This is very likely the result of the
NAM activity of FzM1.8 toward WNT5A. Ly294002 does not
block the binding of FzM1.8 to FZD4, only the intracellular
pathway elicited by the event of binding. Despite the fact that
FZD4/PI3K signaling is not active, FzM1.8 can still bind to
Figure 5. FzM1.8 acts as NAM for FZD4 signaling elicited by WNT5A. (A and B) Dose−response curves for FzM1 and FzM1.8 modulation,
respectively, of WRE activity elicited by WNT5A. Values indicate changes in WRE activity (expressed as a percentage of change over pure WNT5A
activity). (C and D) Dose−response curves for FzM1 and FzM1.8 modulation, respectively, of WRE activity elicited by WNT5A in the presence of
Ly294002. (E) Dose−response curves for WNT5A modulation of WRE activity in the presence of DMSO or the indicated amount of FzM1.8.
Values are reported as means ± sem (n = 5). *P < 0.05.
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FZD4 and act as a NAM toward WNT5A, hampering the
canonical signaling elicited by the orthosteric agonist.
The FZD4/PI3K Axis Preserves the Stemness and
Sustains the Proliferation of Undiﬀerentiated Cells. To
follow at the cellular level the results of the activation of the
FZD4/PI3K pathway by FzM1.8, we used in vitro cultured
CaCo-2 cells. These express endogenous FZD4,42 and as we
have already shown, they respond to FzM1 treatment.15 Upon
treatment with FzM1.8, WNT responsive genes c-myc and cycl-
D1 were upregulated (Figure 6A). On the other hand, FzM1.8
treatment left unaltered the expression of colon stem cell
marker lgr5, indicating that the FZD4/PI3K pathway stimulates
proliferation and preserving the stemness of the cells. FzM1.8
treatment reduces the level of expression of Notch and Sonic
Hedgehog speciﬁc genes pointing toward FzM1.8 speciﬁcity
toward the WNT pathway and a competition between the
FZD4/PI3K axis and the Notch and Sonic Hedgehog pathway
(Figure 6A). Despite promoting proliferation, FzM1.8 treat-
ment did not induce diﬀerentiation of CaCo-2 cells as indicated
by the timing of the appearance of the colonic diﬀerentiation
marker alkaline phosphatase (Figure S13) that was not
inﬂuenced by FzM1.8 treatment.
Finally, the results obtained in CaCo-2 cells were conﬁrmed
in an ex vivo system. Mutations in the APC gene occur very
commonly in patients aﬀected by FAP.43 This genetic disease is
characterized by a hyperactive WNT pathway resulting in the
proliferation of undiﬀerentiated progenitors of the colon crypt
and formation of colonic polyps.1 The latter transform with
high frequency into adenocarcinomas. Human colon biopsies
were cultured in vitro soon after their resection from FAP
patients. In unsupplemented media, these ex vivo samples
duplicate poorly and their growth is rapidly arrested. As
expected, treatment with FzM1 resulted in a decreased rate of
survival of the cultures. Diﬀerently, supplementation of the
culture medium with FzM1.8 resulted in increased rates of
survival and proliferation of the cells (Figure 6B).
Figure 6. FzM1.8 reduces the stemness and increases the rate of proliferation of undiﬀerentiated colon cancer cells. (A) Eﬀect of FzM1.8 or FzM.1
on the expression levels of the WNT (lgr5, c-myc, and cyclin-D1), Notch (notchI and hey-l) and of the Sonic hedgehog (gli1 and gli2) target genes in
CaCo-2 cells. mRNA levels were normalized to those of cyclophilin A. (B) Rate of duplication of human colonic biopsies in culture medium
supplemented with FzM1, FzM1.8, or vehicle. Values are expressed as means ± sem (in panels A and B, n = 3). *P < 0.05.
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■ CONCLUSIONS
Approaching the study of the WNT signaling is a diﬃcult task.
The huge plethora of diﬀerent biological processes in which the
pathway is involved, the many interconnected signaling routes
originating upon binding of a WNT to FZD, and the existence
of diﬀerent WNT/FZD combinations, of FZD oligomers, and
of co-receptors all contribute and make this intracellular
pathway fascinating but complex.
Pure and biologically active WNT proteins are diﬃcult to
obtain because of their lipoprotein nature. The composition of
the widely used WNT-conditioned media is not known and
thus diﬃcult to control. In this scenario, small organic
molecules acting as orthosteric or allosteric agonists for FZDs
represent missing milestones in the WNT signaling ﬁeld. These
could be used in replacement of WNT proteins during in vitro
functional studies, reducing costs and the complexity of
production, or in vivo as drugs to either inhibit or activate
the WNT pathway.41
We here present FzM1.8, a small organic allosteric agonist of
FZD4. In the absence of any WNT ligand, FzM1.8 binds to
FZD4 and activates the WNT/β-catenin pathway by promoting
TCF/LEF transcriptional activity.
FzM1.8 acts by biasing FZD4 signaling toward a non-
canonical route that involves PI3K. FzM1.8 binding stabilizes
FZD4 in a conformational state with an increased aﬃnity for
heterotrimeric G proteins and stimulates the release of the Gβγ
subunit that in turn activates PI3K. The activity seems to
depend on the negative charge that the carboxylic moiety of
FzM1.8 imposes on ICL3 of FZD4.
Dose−response curves for FZD4 modulation by FzM1.8 are
bell-shaped. A very interesting hypothesis explaining this
behavior would be the existence of compensatory actions of
the ligand (e.g., desensitization and receptor downregulation)
as well as indirect modulation of WRE activity (synthesis or
degradation of regulatory proteins) or even a negative feedback
response that becomes activated at high concentrations of
FzM1.8.
However, the results obtained with the mutant FZD4-T425D
point toward a similarly possible yet diﬀerent explanation of the
bell-shaped dose−response curve. This could arise as a result of
partial and full occupancy of a FZD4 oligomer. The mutant
FZD4-T425D activates the WNT/PI3K axis only when co-
expressed with FZD4wt. On the other hand, when expressed
alone, it neither responds to FzM1.8 nor presents increased
basal WRE activity. This could be explained by (i) the
heterocomplex mimicking a FZD4-wt oligomer partially
occupied by FzM1.8 and (ii) a FZD4-T425D homocomplex
mimicking a fully occupied oligomer. In this scenario, the
inhibition we registered upon treatment with a high
concentration of FzM1.8 could arise upon full occupancy of
FZD4 oligomers. Probably when full occupancy occurs, each
FZD4 protomer recruits a heterotrimeric G protein devoting
the entire oligomer exclusively to the FZD4/PI3K axis. This has
been already shown for FZD4. Overexpression of G proteins
inhibits the WNT pathway as consequence of loss of the
correct stoichiometry between FZD oligomers and intracellular
proteins.44
Despite the complexity of explaining the mechanistic details
underpinning the intracellular response to the allosteric ligand,
FzM1.8 will oﬀer us a great opportunity to illuminate, in the
intricate complexity of the WNT/FZD signaling network, one
speciﬁc WNT route, reducing the level of interference of the
many other pathways of which FZD4 could be a part. Using
FzM1.8 as a lead, new analogues will allow the development of
new allosteric molecules selectively recruiting other intracellular
eﬀectors and biasing the WNT pathway toward diﬀerent
intracellular signaling routes.
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